News

Andrew G. Lee, MD, presents the “no” perspective on whether GLP-1 agonists cause non-arteritic anterior ischemic optic neuropathy, arguing that current evidence shows association but not proven causation.

The 17th annual Congress on Controversies in Ophthalmology takes place on 20–21 March 2026 in Kraków, Poland, bringing together an international faculty for two days of structured debate on the most pressing questions in the field.

Ian Pitha, MD, PhD, argues that leveraging large-scale utilization data to identify the highest-impact medications could help the field get ahead of supply disruptions before they reach patients.

Aflibercept briefly reverses severe ROP in tiny preemies, yet nearly half relapse within weeks—prompting laser rescue and renewed safety questions.

Previously, the company had received CRLs from the FDA in April 2025 and November 2023 for NDAs for reproxalap for the treatment of dry eye.

Chiesi Global Rare Diseases said the agency declined to approve its application and requested additional information for the proposed treatment of Leber hereditary optic neuropathy.

See which ophthalmology surgery centers earn US News’ 2026 high-performing badge, where they cluster, and why complication rates drop 40%.

The trial, sponsored by ONL Therapeutics, aims to enroll approximately 324 patients across sites in Europe, the United States, and Canada.

The trial, sponsored by ONL Therapeutics, aims to enrol approximately 324 patients across sites in Europe, the United States, and Canada.

AI-powered polarized-light retinal imaging separates Alzheimer’s from ALS/FTLD deposits with 96% accuracy, promising low-cost early diagnosis.

Study shows RB1-positive infants diagnosed before 9 months face higher fellow-eye retinoblastoma risk, guiding smarter surveillance and de-escalation.

This scenario emphasizes the need to gain an understanding of the role of hearing impairment in vision rehabilitation outcomes, particularly as they relate to functional independence.

The manufacturer notes that TECNIS PureSee is the first US EDOF IOL cleared by the FDA without contrast sensitivity cautions.

According to the manufacturer, TECNIS PureSee is the first US EDOF IOL approved by the FDA with no warning on contrast sensitivity.

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED

According to the company, the lens is the first and only FDA-approved EDOF IOL in the US without a warning regarding loss of contrast sensitivity.

Marta Pazos, MD, PhD, on how OCT and emerging AI can help spot preperimetric glaucoma years before vision loss while avoiding false positives from myopia and disc anatomy.

Experts share practical and research-based advancements, offering actionable strategies in diagnosis, treatment, and early detection.

For Jeffry D. Gerson, OD, FAAO, an early fascination with retinal disease—sparked during residency and shaped by mentorship and emerging OCT technology—led to a career focused on education and OD-MD collaboration.

The BIM-IOL System consists of 2 non-bioerodible drug pads attached to the optic-haptic junction of a monofocal intraocular lens (IOL), which is implanted as part of routine cataract surgery.

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Paula Anne Newman-Casey, MD, MS, explains the multifactorial needs and her decades-long research that resulted in the SEE program for glaucoma patients.

Ophthalmologists report dry eye’s mixed mechanisms, symptom-driven diagnosis, uneven treatment response, and payer hurdles—what needs fixing next.